Literature DB >> 3208454

Measurement of terminal complement complexes in rheumatoid arthritis.

B P Morgan1, R H Daniels, B D Williams.   

Abstract

Though complement activation is recognized as a central event in inflammation in the rheumatoid joint, little attention has been paid to the role of the cytolytic membrane attack complex of complement in the pathogenesis of this disease. The membrane attack complex causes a variety of non-lethal effects in nucleated cells, including stimulation of release of inflammatory mediators, and cell proliferation. Thus in the rheumatoid synovium, non-lethal effects of complement membrane attack may play a major role in disease pathology. In order to investigate this possibility, assays for the detection of terminal complement complexes in biological fluids have been established, and used to demonstrate membrane attack pathway activation in rheumatoid arthritis. Terminal complement complexes were present in increased levels in synovial fluid (mean, 1,334 ng/ml) and plasma (mean, 513 ng/ml) in 20 patients with rheumatoid arthritis when compared with controls (mean, 285 ng/ml and 129 ng/ml respectively). Using an assay specific for the SC5b-9 complex it was demonstrated that the raised levels of terminal complement complexes in rheumatoid synovial fluid consisted of a mixture of inactive SC5b-9 complexes and fluid-phase complement membrane attack complexes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208454      PMCID: PMC1541752     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  STUDIES ON THE DEPRESSED HEMOLYTIC COMPLEMENT ACTIVITY OF SYNOVIAL FLUID IN ADULT RHEUMATOID ARTHRITIS.

Authors:  H HEDBERG
Journal:  Acta Rheumatol Scand       Date:  1963

2.  Activation of the complement system in rheumatoid synovitis.

Authors:  S Ruddy; K F Austen
Journal:  Fed Proc       Date:  1973-02

3.  Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum.

Authors:  S Bhakdi; M Roth
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

4.  Immunoaffinity purification of human complement component C9 using monoclonal antibodies.

Authors:  B P Morgan; R A Daw; K Siddle; J P Luzio; A K Campbell
Journal:  J Immunol Methods       Date:  1983-11-25       Impact factor: 2.303

5.  Synovial fluid total hemolytic complement activity in rheumatic diseases - a reappraisal.

Authors:  H Sheppeard; D J Lea; D J Ward
Journal:  J Rheumatol       Date:  1981 May-Jun       Impact factor: 4.666

6.  Ninth component of complement: self-aggregation and interaction with lipids.

Authors:  J R Dankert; J W Shiver; A F Esser
Journal:  Biochemistry       Date:  1985-05-21       Impact factor: 3.162

7.  Molecular weight of the membrane C5b-9 complex of human complement: characterization of the terminal complex as a C5b-9 monomer.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

8.  Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay.

Authors:  T E Mollnes
Journal:  Scand J Immunol       Date:  1985-06       Impact factor: 3.487

9.  Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical features.

Authors:  F C Hay; L J Nineham; R Perumal; I M Roitt
Journal:  Ann Rheum Dis       Date:  1979-02       Impact factor: 19.103

10.  Neoantigen of the membrane attack complex of human complement: Occurrence on peripheral blood leukocytes from patients with systemic lupus erythematosus.

Authors:  J G Curd; J S Sundsmo; W P Kolb; H G Bluestein; H J Müller-Eberhard
Journal:  Arthritis Rheum       Date:  1978-03
View more
  33 in total

1.  Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA).

Authors:  M A Friese; J Hellwage; T S Jokiranta; S Meri; H J Müller-Quernheim; H H Peter; H Eibel; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

3.  Measurement of complement activation products in patients with chronic rheumatic diseases.

Authors:  G Auda; E R Holme; J E Davidson; A Zoma; J Veitch; K Whaley
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

4.  Human rheumatoid synovial cell stimulation by the membrane attack complex and other pore-forming toxins in vitro: the role of calcium in cell activation.

Authors:  R H Daniels; B D Williams; B P Morgan
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

5.  T cell activation by terminal complex of complement and immune complexes.

Authors:  Anil K Chauhan; Terry L Moore
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

Review 6.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

7.  Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease.

Authors:  A P Weetman; S B Cohen; D A Oleesky; B P Morgan
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

8.  Apolipoprotein E Triggers Complement Activation in Joint Synovial Fluid of Rheumatoid Arthritis Patients by Binding C1q.

Authors:  Leonie M Vogt; Ewa Kwasniewicz; Simone Talens; Carsten Scavenius; Ewa Bielecka; Kristina N Ekdahl; Jan J Enghild; Matthias Mörgelin; Tore Saxne; Jan Potempa; Anna M Blom
Journal:  J Immunol       Date:  2020-04-06       Impact factor: 5.422

9.  Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.

Authors:  C L Harris; A S Williams; S M Linton; B P Morgan
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

10.  Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis.

Authors:  M A Friese; T Manuelian; S Junnikkala; J Hellwage; S Meri; H H Peter; D L Gordon; H Eibel; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.